scientific-writer 2.2.1__py3-none-any.whl → 2.2.3__py3-none-any.whl

scientific_writer/.claude/skills/clinical-reports/references/diagnostic_reports_standards.md

@@ -0,0 +1,629 @@
+# Diagnostic Reports Standards
+
+## Radiology Reporting Standards
+
+### American College of Radiology (ACR) Guidelines
+
+The ACR provides comprehensive practice parameters for diagnostic imaging reporting to ensure quality, consistency, and communication effectiveness.
+
+#### Core Radiology Report Components
+
+**1. Patient Demographics**
+- Patient name and/or unique identifier
+- Date of birth or age
+- Sex
+- Medical record number
+- Examination date and time
+- Referring physician
+
+**2. Procedure/Examination**
+- Specific examination performed
+- Anatomical region
+- Laterality (right, left, bilateral)
+- Technique and protocol
+- Example: "MRI Brain without and with Contrast"
+
+**3. Clinical Indication**
+- Reason for examination
+- Relevant clinical history
+- Specific clinical question
+- ICD-10 codes (when required)
+- Example: "Headache and visual disturbances. Rule out intracranial mass."
+
+**4. Comparison**
+- Prior relevant imaging studies
+- Dates of prior studies
+- Modality of prior studies
+- Availability for comparison
+- Example: "Comparison: CT head without contrast from 6 months prior (January 15, 2023)"
+
+**5. Technique**
+- Imaging parameters and protocol
+- Contrast administration details:
+  - Type (iodinated, gadolinium)
+  - Route (IV, oral, rectal)
+  - Volume administered
+  - Timing of imaging
+- Technical quality statement
+- Radiation dose (for CT)
+- Limitations or technical issues
+- Example:
+  ```
+  Technique: Multiplanar T1 and T2-weighted sequences were obtained through
+  the brain without and with IV contrast. 15 mL of gadolinium-based contrast
+  agent was administered intravenously. Technical quality is adequate.
+  ```
+
+**6. Findings**
+- Systematic description of imaging findings
+- Organized by anatomical region or organ system
+- Measurements of abnormalities (size, volume)
+- Specific descriptive terminology
+- Pertinent positive findings
+- Relevant negative findings
+- Comparison to prior studies when available
+
+**Organization approaches:**
+- Organ-by-organ (for abdomen/pelvis)
+- Region-by-region (for chest)
+- System-by-system (for spine)
+- Compartment-by-compartment (for musculoskeletal)
+
+**7. Impression/Conclusion**
+- Summary of key findings
+- Diagnosis or differential diagnosis
+- Answers to clinical question
+- Level of concern or urgency
+- Comparison to prior (improved, stable, worsened)
+- Recommendations for further imaging or clinical management
+- Clear and concise (often numbered list)
+
+Example:
+```
+IMPRESSION:
+1. 3.2 cm enhancing mass in the right frontal lobe with surrounding vasogenic
+   edema, most consistent with high-grade glioma. Metastasis cannot be excluded.
+   Clinical correlation and tissue sampling recommended.
+2. No acute intracranial hemorrhage or herniation.
+3. Recommend neurosurgical consultation.
+```
+
+**8. Critical Results Communication**
+- Urgent or unexpected findings requiring immediate action
+- Direct communication to ordering provider documented
+- Time, date, and recipient of verbal communication
+- Example: "Critical result: Acute pulmonary embolism. Dr. Smith paged at 14:35 on [date]."
+
+### Structured Reporting Systems
+
+#### Lung-RADS (Lung CT Screening Reporting and Data System)
+
+Used for lung cancer screening CT interpretation.
+
+**Categories:**
+- **Lung-RADS 0**: Incomplete - additional imaging needed
+- **Lung-RADS 1**: Negative - no nodules, definitely benign nodules
+- **Lung-RADS 2**: Benign appearance or behavior - nodules with very low likelihood of malignancy
+- **Lung-RADS 3**: Probably benign - short-interval follow-up suggested
+- **Lung-RADS 4A**: Suspicious - 3-month follow-up or PET/CT
+- **Lung-RADS 4B**: Very suspicious - 3-month follow-up or PET/CT, consider biopsy
+- **Lung-RADS 4X**: Very suspicious with additional features, consider biopsy
+
+**Management recommendations included for each category**
+
+#### BI-RADS (Breast Imaging Reporting and Data System)
+
+Standardized lexicon for breast imaging (mammography, ultrasound, MRI).
+
+**Categories:**
+- **BI-RADS 0**: Incomplete - need additional imaging
+- **BI-RADS 1**: Negative - no abnormalities
+- **BI-RADS 2**: Benign findings
+- **BI-RADS 3**: Probably benign - short-interval follow-up (6 months)
+- **BI-RADS 4**: Suspicious - biopsy recommended
+  - 4A: Low suspicion
+  - 4B: Moderate suspicion
+  - 4C: High suspicion
+- **BI-RADS 5**: Highly suggestive of malignancy - biopsy recommended
+- **BI-RADS 6**: Known biopsy-proven malignancy
+
+**Descriptors:**
+- Mass: Shape, margin, density
+- Calcifications: Morphology, distribution
+- Asymmetry: Type and characteristics
+- Associated features
+
+#### LI-RADS (Liver Imaging Reporting and Data System)
+
+For reporting liver observations in patients at risk for hepatocellular carcinoma.
+
+**Categories:**
+- **LI-RADS 1**: Definitely benign
+- **LI-RADS 2**: Probably benign
+- **LI-RADS 3**: Intermediate probability of malignancy
+- **LI-RADS 4**: Probably HCC
+- **LI-RADS 5**: Definitely HCC
+- **LI-RADS M**: Probably or definitely malignant, not HCC-specific
+- **LI-RADS TIV**: Tumor in vein
+
+**Major features assessed:**
+- Size
+- Enhancement pattern (arterial phase hyperenhancement, washout)
+- Capsule appearance
+- Threshold growth
+
+#### PI-RADS (Prostate Imaging Reporting and Data System)
+
+For multiparametric MRI of the prostate.
+
+**Assessment categories:**
+- **PI-RADS 1**: Very low - clinically significant cancer highly unlikely
+- **PI-RADS 2**: Low - clinically significant cancer unlikely
+- **PI-RADS 3**: Intermediate - equivocal
+- **PI-RADS 4**: High - clinically significant cancer likely
+- **PI-RADS 5**: Very high - clinically significant cancer highly likely
+
+**Evaluation:**
+- Peripheral zone: DWI/ADC primary determinant
+- Transition zone: T2-weighted primary determinant
+- DCE (dynamic contrast-enhanced): Used for PI-RADS 3 lesions in peripheral zone
+
+### RadLex and Standardized Terminology
+
+**RadLex** is a comprehensive lexicon for radiology developed by the Radiological Society of North America (RSNA).
+
+**Benefits:**
+- Standardized terminology
+- Improved communication
+- Enables data mining and analytics
+- Facilitates decision support systems
+- Consistent report structure
+
+**Common RadLex terms:**
+- Anatomical structures
+- Imaging observations
+- Disease entities
+- Procedures
+
+### Radiological Measurements
+
+**Linear measurements:**
+- Use bidimensional (length × width) or tridimensional (length × width × height)
+- Report largest dimension for nodules/masses
+- Consistent measurement methodology for follow-up
+- Perpendicular measurements when possible
+
+**Volumetric measurements:**
+- More accurate for follow-up of irregular lesions
+- Automated or semi-automated software
+- Particularly useful for lung nodules
+
+**Response assessment:**
+- RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
+  - Target lesions: sum of longest diameters (maximum 5 lesions, 2 per organ)
+  - Complete response, partial response, stable disease, progressive disease
+
+## Pathology Reporting Standards
+
+### College of American Pathologists (CAP) Protocols
+
+CAP cancer protocols provide standardized synoptic reporting templates for cancer specimens.
+
+#### Synoptic Reporting Elements
+
+**Core elements for all cancer specimens:**
+
+**1. Specimen Information**
+- Procedure type (biopsy, excision, resection)
+- Specimen laterality
+- Specimen integrity and adequacy
+
+**2. Tumor Site**
+- Anatomical site and subsite
+- Precise location within organ
+
+**3. Tumor Size**
+- Greatest dimension in cm
+- Additional dimensions if 3D measurement relevant
+- Method of measurement (gross vs. microscopic)
+
+**4. Histologic Type**
+- WHO classification
+- Specific subtype
+- Percentage of each component in mixed tumors
+
+**5. Histologic Grade**
+- Grading system used (e.g., Nottingham, Fuhrman, Gleason)
+- Grade category (well, moderately, poorly differentiated OR G1, G2, G3)
+- Individual component scores if applicable
+
+**6. Extent of Invasion**
+- Depth of invasion (measured in mm)
+- Involvement of adjacent structures
+- Lymphovascular invasion (present/not identified)
+- Perineural invasion (present/not identified)
+
+**7. Margins**
+- Closest margin distance
+- Margin status for each margin assessed (negative/positive)
+- Specific margin(s) involved if positive
+
+**8. Lymph Nodes**
+- Number of lymph nodes examined
+- Number of lymph nodes with metastasis
+- Size of largest metastatic deposit
+- Extranodal extension (present/absent)
+
+**9. Pathologic Stage (pTNM)**
+- pT: Primary tumor extent
+- pN: Regional lymph nodes
+- pM: Distant metastasis (if known)
+- AJCC Cancer Staging Manual edition used
+
+**10. Additional Findings**
+- Treatment effect (if post-neoadjuvant therapy)
+- Associated lesions (dysplasia, carcinoma in situ)
+- Background tissue (cirrhosis, inflammation)
+
+**11. Ancillary Studies**
+- Immunohistochemistry results
+- Molecular/genetic testing results
+- Biomarker status (e.g., ER, PR, HER2 for breast; MSI for colon)
+- FISH or other cytogenetic results
+
+#### Organ-Specific CAP Protocols
+
+**Breast Cancer:**
+- Histologic type (invasive ductal, lobular, special types)
+- Nottingham grade (tubule formation, nuclear pleomorphism, mitotic count)
+- ER/PR status (percentage and intensity)
+- HER2 status (IHC score, FISH if needed)
+- Ki-67 proliferation index
+- DCIS component (if present)
+- Response to neoadjuvant therapy (residual cancer burden)
+
+**Colorectal Cancer:**
+- Histologic type (adenocarcinoma, mucinous, etc.)
+- Grade
+- Depth of invasion (into submucosa, muscularis propria, pericolic tissue, etc.)
+- Tumor deposits
+- Lymph nodes (number positive/total examined)
+- Margins (proximal, distal, radial/circumferential)
+- MSI/MMR status
+- KRAS, NRAS, BRAF mutations
+
+**Prostate Cancer:**
+- Gleason score (primary + secondary pattern)
+- Grade group (1-5)
+- Percentage of tissue involved
+- Extraprostatic extension
+- Seminal vesicle invasion
+- Surgical margin status
+- Lymph nodes if sampled
+
+**Lung Cancer:**
+- Histologic type (adenocarcinoma, squamous, small cell, etc.)
+- Grade (for NSCLC)
+- Invasion depth
+- Visceral pleural invasion
+- Distance to margins
+- Lymph nodes
+- Molecular markers (EGFR, ALK, ROS1, PD-L1)
+
+### Gross Pathology Description
+
+**Essential elements:**
+- Specimen labeling and identification
+- Type of specimen
+- Dimensions and weight
+- Orientation markers (if present)
+- External surface description
+- Cut surface appearance
+- Lesion description:
+  - Size (3 dimensions)
+  - Location
+  - Color
+  - Consistency
+  - Borders (well-circumscribed, infiltrative)
+  - Distance to margins
+- Sampling approach (how tissue was sectioned and submitted)
+
+**Example:**
+```
+GROSS DESCRIPTION:
+Received fresh, labeled with patient name and "left breast, lumpectomy" is an
+oriented lumpectomy specimen measuring 8.5 x 6.0 x 4.0 cm, with a suture
+indicating superior margin. Inking: superior - blue, inferior - black, medial -
+green, lateral - red, anterior - orange, posterior - yellow. Serially sectioned
+to reveal a firm, gray-white mass measuring 2.1 x 1.8 x 1.5 cm, located 2.5 cm
+from superior, 3.0 cm from inferior, 2.0 cm from medial, 3.5 cm from lateral,
+1.5 cm from anterior, and 1.8 cm from posterior margins. Representative sections
+submitted as follows: A1-A3 tumor, A4 superior margin, A5 medial margin, A6
+posterior margin.
+```
+
+### Microscopic Description
+
+**Key elements:**
+- Architectural pattern
+- Cellular characteristics
+  - Cell type
+  - Nuclear features (size, shape, chromatin, nucleoli)
+  - Cytoplasmic features
+  - Mitotic activity
+- Degree of differentiation
+- Invasion pattern
+- Special features (necrosis, hemorrhage, calcification)
+- Stroma and background tissue
+- Lymphovascular or perineural invasion
+- Margins (distance and status)
+- Lymph nodes (description of metastases)
+
+### Frozen Section Reporting
+
+**Indications:**
+- Intraoperative diagnosis
+- Margin assessment
+- Lymph node evaluation
+- Tissue triage
+
+**Report format:**
+- "Frozen section diagnosis" clearly labeled
+- Intraoperative consultation note
+- Time of frozen section
+- Specimen description
+- Frozen section diagnosis
+- Note: "Permanent sections to follow"
+
+**Frozen section disclaimers:**
+- Limited by frozen artifact
+- Final diagnosis on permanent sections
+- Defer to permanent sections for definitive diagnosis
+
+### Diagnostic Certainty Language
+
+**Definitive:**
+- "Consistent with..."
+- "Diagnostic of..."
+- "Positive for..."
+
+**Probable:**
+- "Consistent with..."
+- "Favor..."
+- "Most likely..."
+
+**Possible:**
+- "Suggestive of..."
+- "Cannot exclude..."
+- "Differential diagnosis includes..."
+
+**Defer:**
+- "Defer to..."
+- "Recommend..."
+- "Additional studies pending..."
+
+## Laboratory Reporting Standards
+
+### Clinical Laboratory Standards Institute (CLSI) Guidelines
+
+CLSI provides standards for laboratory testing and reporting.
+
+#### Laboratory Report Components
+
+**1. Patient Demographics**
+- Patient name and identifier
+- Date of birth or age
+- Sex
+- Ordering provider
+
+**2. Specimen Information**
+- Specimen type (blood, serum, plasma, urine, CSF, etc.)
+- Collection date and time
+- Received date and time
+- Specimen condition
+- Fasting status (if relevant)
+
+**3. Test Information**
+- Test name (full, not just abbreviation)
+- Test code
+- Methodology
+- Accession or specimen number
+
+**4. Results**
+- Quantitative value with units
+- Qualitative result (positive/negative, detected/not detected)
+- Reference range or interval
+- Flags for abnormal results
+  - H = High
+  - L = Low
+  - Critical or panic values highlighted
+
+**5. Reference Intervals**
+- Age-specific
+- Sex-specific
+- Population-specific (when relevant)
+- Method-specific
+- Units clearly stated
+
+**Example:**
+```
+Test: Hemoglobin A1c
+Result: 8.2%  (H)
+Reference Range: 4.0-5.6% (non-diabetic)
+Method: HPLC
+Interpretation: Consistent with poorly controlled diabetes
+```
+
+**6. Interpretative Comments**
+- When result requires context
+- Suggests additional testing
+- Explains interferences or limitations
+- Provides clinical guidance
+
+**7. Quality Control**
+- Delta checks (comparison to prior values)
+- Critical values and read-back procedure
+- Specimen quality issues (hemolysis, lipemia, icterus)
+- Dilutions performed
+- Repeat testing if needed
+
+### LOINC (Logical Observation Identifiers Names and Codes)
+
+Standard coding system for laboratory and clinical observations.
+
+**LOINC code components:**
+- Component (analyte measured)
+- Property (mass, substance concentration, etc.)
+- Timing (point in time, 24-hour)
+- System (specimen type)
+- Scale (quantitative, ordinal, nominal)
+- Method (when relevant)
+
+**Example:**
+- Hemoglobin A1c in Blood: 4548-4
+- Glucose in Serum/Plasma: 2345-7
+- Creatinine in Serum/Plasma: 2160-0
+
+### Critical Value Reporting
+
+**Definition:** Results that indicate life-threatening conditions requiring immediate clinical action.
+
+**Critical value examples:**
+- Glucose: <40 mg/dL or >500 mg/dL
+- Potassium: <2.5 mEq/L or >6.5 mEq/L
+- Sodium: <120 mEq/L or >160 mEq/L
+- Calcium: <6.0 mg/dL or >13.0 mg/dL
+- WBC: <1.0 × 10³/μL or >50 × 10³/μL
+- Hemoglobin: <5.0 g/dL
+- Platelets: <20 × 10³/μL
+- INR: >5.0 (on warfarin)
+- Positive blood culture
+- Positive CSF culture or gram stain
+
+**Critical value procedure:**
+1. Result identified by laboratory
+2. Immediate contact with ordering provider or designee
+3. Read-back verification
+4. Documentation:
+   - Date and time
+   - Person contacted
+   - Person receiving notification
+   - Test and result
+5. Follow facility policy for unable to reach provider
+
+### Microbiology Reporting
+
+**Culture reports:**
+- Specimen type and source
+- Organisms identified
+- Quantity (light, moderate, heavy growth)
+- Antimicrobial susceptibility results
+- Interpretation (susceptible, intermediate, resistant)
+- MIC values when applicable
+
+**Gram stain reports:**
+- Bacteria present (Gram-positive/negative, morphology)
+- Quantity and cellular context
+- WBCs or other cells present
+
+**Preliminary reports:**
+- Issued before final identification
+- Clearly labeled "PRELIMINARY"
+- Final report to follow
+
+**Final reports:**
+- Definitive organism identification
+- Complete susceptibility panel
+- Interpretative comments
+
+### Molecular Pathology/Genomics Reporting
+
+**Components:**
+- Gene(s) tested
+- Variant(s) detected
+- Classification (pathogenic, likely pathogenic, VUS, likely benign, benign)
+- Allele frequency
+- Methodology (NGS, Sanger sequencing, PCR, etc.)
+- Reference sequence
+- Clinical significance and interpretation
+- Recommendations (treatment implications, family testing)
+- Limitations of testing
+
+**Example:**
+```
+Test: BRCA1/BRCA2 Full Gene Sequencing
+Result: PATHOGENIC VARIANT DETECTED
+Gene: BRCA1
+Variant: c.68_69delAG (p.Glu23ValfsTer17)
+Classification: Pathogenic
+Interpretation: This variant is associated with increased risk of breast and
+ovarian cancer. Genetic counseling and risk-reducing strategies recommended.
+Family testing should be considered.
+```
+
+### Point-of-Care Testing (POCT)
+
+**Requirements:**
+- Same quality standards as central laboratory
+- Operator competency documentation
+- Quality control documentation
+- Maintenance records
+- Result documentation in medical record
+
+**Common POCT:**
+- Blood glucose
+- Hemoglobin/hematocrit
+- INR
+- Blood gas
+- Pregnancy test
+- Urinalysis
+- Rapid strep
+- Influenza
+
+## Quality Indicators for Diagnostic Reports
+
+### Radiology Quality Metrics
+
+- Report turnaround time (routine vs. urgent)
+- Critical result communication time
+- Report error rates
+- Addendum rate
+- Referring physician satisfaction
+
+**Benchmarks:**
+- Routine reports: <24 hours
+- Urgent reports: <4 hours
+- STAT reports: <1 hour
+- Critical findings: Immediate verbal communication
+
+### Pathology Quality Metrics
+
+- Turnaround time (TAT) for different specimen types
+- Frozen section accuracy
+- Amendment rate
+- Specimen adequacy rate
+- Immunohistochemistry QC
+
+**TAT benchmarks:**
+- Surgical pathology routine: 2-3 days
+- Surgical pathology complex: 5-7 days
+- Cytology: 1-2 days
+- Frozen section: 15-20 minutes intraoperatively
+
+### Laboratory Quality Metrics
+
+- TAT from collection to result
+- Critical value notification time
+- Specimen rejection rate
+- Proficiency testing performance
+- Delta check failure rate
+
+**TAT benchmarks:**
+- STAT laboratory: <60 minutes
+- Routine laboratory: 2-4 hours
+- Send-out tests: Per reference laboratory
+
+---
+
+This reference provides comprehensive standards for diagnostic reporting across radiology, pathology, and laboratory medicine. Refer to these guidelines to ensure reports meet professional standards and regulatory requirements.
+